Archives
-
From RNA Signal to Translation: Better Delivery Readouts
2026-09-24
Translational mRNA research needs to distinguish cellular association from productive protein expression. This article explains how dual-fluorescence measurements, careful controls, and evidence-aware assay design can strengthen delivery-system decisions, with ARCA Cy5 EGFP mRNA (5-moUTP) as a practical research tool.
-
Dual TLR2/4 Inhibition in Oxygen-Induced Retinopathy
2026-09-24
Dayoub et al. evaluated AVR-121 and AVR-123, small molecules that inhibit both TLR2 and TLR4, across immune-cell, retinal endothelial-cell, and mouse oxygen-induced retinopathy models. Their findings support investigating stage-specific inflammatory signaling as a way to reduce retinal vascular injury and abnormal neovascularization, while emphasizing that the compounds are not selective TLR4 inhibitors and the results do not establish clinical efficacy.
-
Rocilinostat: Selective HDAC6 Inhibition in Translation
2026-09-23
Rocilinostat (ACY-1215) gives translational researchers a selective way to probe HDAC6 biology, from α-tubulin acetylation to proteasome-inhibitor combinations in multiple myeloma models. This article connects mechanism to experimental design while clarifying the evidence boundaries.
-
Using (R)-MG132 for Proteasome Assay Rigor
2026-09-23
(R)-MG132 is a functionally inactive MG-132 enantiomer designed to expose nonspecific effects that can be mistaken for proteasome inhibition. This guide shows how to pair it with active inhibitor conditions, cell-based assays, and mechanistic studies of cancer metabolism for more defensible conclusions.
-
HDAC Inhibition Reverses EBV-Driven NPC Plasticity
2026-09-22
The reference study identifies an epigenetic mechanism by which EBV latent membrane protein 1 drives dedifferentiation and stem-like plasticity in nasopharyngeal carcinoma. It further shows that HDAC inhibition can restore CEBPA expression and partially reverse this state, providing a mechanistic basis for differentiation-oriented treatment strategies in solid tumors.
-
Mithramycin A: Mechanism and Research Use
2026-09-22
Mithramycin A is an anticancer antibiotic that binds G-C-rich DNA in the presence of divalent metal ions and suppresses transcription-related processes. Its reported c-myc regulation and HL-60 differentiation effects support focused leukemia research and cancer biology research, but the compound is intended for scientific research use only.
-
Tirbanibulin Rewires HPV-Linked Oncogenic Signaling
2026-09-21
A 2024 study in HeLa cells shows that tirbanibulin suppresses proliferation at nanomolar concentrations while reducing HPV-18 oncoproteins and multiple Src-linked signaling proteins. The findings connect tirbanibulin’s established antiproliferative activity with altered cell-cycle, invasion, translation, and apoptosis-associated protein expression, although the mechanism remains primarily correlative and requires validation beyond this cell model.
-
Dual TLR2/4 Inhibition in Oxygen-Induced Retinopathy
2026-09-21
The reference study identifies AVR-121 and AVR-123 as dual TLR2/4 inhibitors that suppress inflammatory and pathological angiogenic responses associated with oxygen-induced retinopathy. Its strongest contribution is the in vivo demonstration that AVR-123 can reduce vaso-obliteration, neovascularization, and inflammatory cytokine changes while preserving the physiological VEGF response in juvenile mouse eyes.
-
Topotecan B4982: Reproducible Cytotoxicity Assays
2026-09-20
A scenario-based guide to using Topotecan (SKU B4982) in viability, proliferation, apoptosis, and drug-resistance studies. It connects mechanism, formulation, concentration selection, ABCG2 biology, and vendor evaluation to practical cancer research workflows.
-
Tiamulin: From Ribosome Binding to Veterinary Translation
2026-09-19
Tiamulin (Thiamutilin) is examined from ribosomal target engagement through pharmacodynamic exposure and veterinary application. This evidence-centered guide shows how molecular footprinting, assay design, and translational constraints can improve interpretation beyond routine protocol optimization.
-
Novobiocin Workflows for Resistance Research
2026-09-18
Build clearer susceptibility, membrane-dynamics, antiparasitic, and antiviral assays with Novobiocin, an aminocoumarin antibiotic that links bacterial DNA replication to broader cellular phenotypes. This guide emphasizes concentration design, resistant-staphylococci comparisons, formulation control, and practical troubleshooting.
-
ATRNL1 and Cell-Type Signals in Atrial Fibrillation
2026-09-18
This study uses large-scale single-nucleus RNA sequencing to define cell-type-specific transcriptional changes in human left atrial tissue from patients with atrial fibrillation. Its identification of ATRNL1 dysregulation in cardiomyocytes, followed by functional perturbation in human stem cell-derived cardiomyocytes, links this gene to cellular stress responses and cardiac electrical activity.
-
SFRP1, Neutrophils, and Wnt Signaling in Oral Fibrosis
2026-09-17
A 2024 study links reduced SFRP1 with neutrophil infiltration, fibrosis, and increased Wnt/β-catenin pathway activity in an arecoline-induced oral submucous fibrosis model. SFRP1 overexpression reduced these pathological features, whereas pathway activation weakened its protective effects, supporting a mechanistic connection between inflammatory recruitment and fibrotic signaling.
-
ATS-9R for Targeted Gene Silencing in Adipocytes
2026-09-17
ATS-9R combines Prohibitin recognition with nona-arginine-mediated nucleic acid condensation for targeted delivery to white adipose tissue. This workflow supports gene silencing in adipocytes and adipose tissue macrophages while providing practical controls for formulation, tissue distribution, and metabolic readouts.
-
Ribonuclease R Workflow for Circular RNA Studies
2026-09-16
Learn how topology-selective RNA digestion can enrich circular transcripts for validation, sequencing, and mechanistic studies. This workflow pairs Ribonuclease R with no-enzyme controls and orthogonal assays so RNase resistance is interpreted as evidence—not proof—of circularity.